JPH05508320A - Hivパッケージング配列を含むベクター、パッケージング不全hivベクター及びその使用 - Google Patents
Hivパッケージング配列を含むベクター、パッケージング不全hivベクター及びその使用Info
- Publication number
- JPH05508320A JPH05508320A JP3511282A JP51128291A JPH05508320A JP H05508320 A JPH05508320 A JP H05508320A JP 3511282 A JP3511282 A JP 3511282A JP 51128291 A JP51128291 A JP 51128291A JP H05508320 A JPH05508320 A JP H05508320A
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- vector
- nucleotides
- gene
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 title claims description 168
- 238000004806 packaging method and process Methods 0.000 title claims description 41
- 230000002950 deficient Effects 0.000 title description 13
- 210000004027 cell Anatomy 0.000 claims description 118
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 114
- 108090000623 proteins and genes Proteins 0.000 claims description 104
- 239000002773 nucleotide Substances 0.000 claims description 77
- 125000003729 nucleotide group Chemical group 0.000 claims description 76
- 230000008488 polyadenylation Effects 0.000 claims description 24
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 22
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 108091081024 Start codon Proteins 0.000 claims description 17
- 230000000692 anti-sense effect Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
- 108700004025 env Genes Proteins 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 238000011144 upstream manufacturing Methods 0.000 claims description 13
- 230000003612 virological effect Effects 0.000 claims description 12
- 238000001890 transfection Methods 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 238000010839 reverse transcription Methods 0.000 claims description 8
- 101150030339 env gene Proteins 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 208000031886 HIV Infections Diseases 0.000 claims description 5
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 5
- 102000053642 Catalytic RNA Human genes 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 102100034353 Integrase Human genes 0.000 claims description 3
- 108010078428 env Gene Products Proteins 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 108010043277 recombinant soluble CD4 Proteins 0.000 claims description 3
- 108700004030 rev Genes Proteins 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 101150098213 rev gene Proteins 0.000 claims description 2
- 108700004026 gag Genes Proteins 0.000 claims 7
- 101150098622 gag gene Proteins 0.000 claims 7
- 210000002845 virion Anatomy 0.000 claims 4
- 101710177291 Gag polyprotein Proteins 0.000 claims 2
- 101710125418 Major capsid protein Proteins 0.000 claims 2
- 101710150344 Protein Rev Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 108010089520 pol Gene Products Proteins 0.000 claims 1
- 108700004029 pol Genes Proteins 0.000 claims 1
- 101150088264 pol gene Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 51
- 239000006228 supernatant Substances 0.000 description 25
- 238000012217 deletion Methods 0.000 description 17
- 230000037430 deletion Effects 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102100034349 Integrase Human genes 0.000 description 11
- 108020000999 Viral RNA Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 102000006392 myotrophin Human genes 0.000 description 8
- 108010058605 myotrophin Proteins 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
- 241000713311 Simian immunodeficiency virus Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000007790 scraping Methods 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 101710205625 Capsid protein p24 Proteins 0.000 description 5
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 5
- 101710177166 Phosphoprotein Proteins 0.000 description 5
- 101710149279 Small delta antigen Proteins 0.000 description 5
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 4
- 241001068263 Replication competent viruses Species 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 101710121417 Envelope glycoprotein Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101710201961 Virion infectivity factor Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 101150084750 1 gene Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108700010908 HIV-1 proteins Proteins 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 241000713675 Spumavirus Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000017960 syncytium formation Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 244000005894 Albizia lebbeck Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000003907 Cyclin I Human genes 0.000 description 1
- 108090000264 Cyclin I Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100152865 Danio rerio thraa gene Proteins 0.000 description 1
- 101150014361 Delta gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 244000203494 Lens culinaris subsp culinaris Species 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 241001077660 Molo Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000713711 Primate lentivirus group Species 0.000 description 1
- 241000208474 Protea Species 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004896 Sulfotransferases Human genes 0.000 description 1
- 108090001033 Sulfotransferases Proteins 0.000 description 1
- 229940126530 T cell activator Drugs 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004298 light response Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 238000000730 protein immunoprecipitation Methods 0.000 description 1
- 101150022630 prp5 gene Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 101150117196 tra-1 gene Proteins 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)HIVセグメントと表記する、HIVゲノムに対応しており機能性H IVタンパク質をコードするのに十分な数のヌクレオチドを含んでいるが、HI Vパッケージングセグメントと表記する、HIVゲノムの5′主要スプライス供 与部位とgag遺伝子の間のヌクレオチドに対応しておりHIV RNAを有効 にパッケージするのに十分な数のヌクレオチドは含んでおらず、 (b)前記HIVセグメントの上流にあるプロモーターを含んでおり、 (c)前記HIVセグメントの下流にありポリアデニル化配列に対応する十分な 数のヌクレオチドを含んでいるが、機能性LTRに対応する十分な数の配列は含 まないベクター。 2.全てのHIV遺伝子に対応するヌクレオチドのうち全てのH1V遺伝子によ ってコードされる機能性タンパク質をコードするのに十分な数のヌクレオチドを 含まない請求項1に記載のベクター。 3.env遺伝子に対応するヌクレオチドのうち機能性envタンパク質をコー ドするのに十分な数のヌクレオチドを含まない請求項2に記載のベクター。 4.gag遺伝子に対応するヌクレオチドのうち機能性gagタンパク質をコー ドするのに十分な数のヌクレオチドを含まない請求項2に記載のベクター。 5.HIV構造遺伝子に対応するヌクレオチドのうち全ての構造遺伝子によって コードされる機能性タンパク質をコードするのに十分な数のヌクレオチドを含ま ない請求項1に記載のベクター。 6.前記プロモーターがHIV LTRである請求項1に記載のベクター。 7.前記HIVパッケージングセグメントが、5′主要スプライス供与部位から 下流に向かってgag遺伝子開始コドンの約5塩基上流までのヌクレオチド配列 である請求項1に記載のベクター。 8.前記HIVゲノムが、HIV−1、HIV−2及びSIVからなる群から選 択されている請求項1に記載のベクター。 9.前記HIVゲノムがHIV−1ゲノムである請求項1に記載のベクター。 10.前記HIVゲノムがHIV−2ゲノムである請求項1に記載のベクター。 11.前記HIVセグメントが、gag遺伝子及びpol遺伝子に対応すろヌク レオチドのうち機能性gag及びpolタンパク質を産生するのに十分な数のヌ クレオチドを含む請求項2に記載のベクター。 12.前記HIVセグメントが、env遺伝子に対応するヌクレオチドのうち機 能性envタンパク質を産生するのに十分な数のヌクレオチドを含む請求項2に 記載のベクター。 13.前記プロモーターがHIV LTRである請求項11に記載のベクター。 14.前記プロモーターがHIV LTRである請求項12に記載のベクター。 15.前記ポリアデニル化配列がSV40ポリアデニル化配列である請求項1に 記載のベクター。 16.前記ポリアデニル化配列がSV40ポリアデニル化配列である請求項11 に記載のベクター。 17.前記ポリアデニル化配列がSV40ポリアデニル化配列である請求項12 に記載のベクター。 18.前記HIVセグメントが、rev遺伝子に対応するヌクレオチドのうち機 能住revタンパク質を産生するのに十分な数のヌクレオチドを含む請求項17 に記載のベクター。 19.(a)予め選択した遺伝子及び前記予め選択した遺伝子のためのプロモー ターと、 (b)HIVパッケージング配列と表記する、HIVパッケージング配列に対応 しておりHIV RNAをパッケージするのに十分な数のヌクレオチド とを含むベクターであって、HIV LTR配列と表記する、発現、逆転写及び 親込みされるのに十分な数のHIVLTR及びそのフランキング配列に対応する ヌクレオチドに対応する配列で各側部がブランキングされており、前記HIVパ ッケージング配列及びHIV LTR配列が同じHIVゲノムに対応しているベ クター。 20,前記HIV LTR配列の1つが、前記予め選択された遺伝子のためのプ ロモーターとして作用する請求項19に記載のベクター。 21.前記予め選択された遺伝子のためのプロモーターとして前記HIV LT R配列に加えて別のプロモーター配列がある請求項19に記載のベクター。 22.前記予め選択された遺伝子の隣にポリアデニル化配列に対応するヌクレオ チド配列がある請求項19に記載のベクター。 23.第2の予め選択された遺伝子を含む請求項19に記載のベクター。 24.前記HIVパッケージング配列が、5′主要スプライス供与部位からga g遺伝子の最も5′側にある部位までのヌクレオチドに対応している請求項19 に記載のベクター。 25.前記gag遺伝子の最も5′側にある部位が、HIV−1ヌクレオチドの 約338〜385の間である請求項24に記載のベクター。 26.前記部位が、HIV−1ヌクレオチドの約350〜約381の間にある請 求項25に記載のベクター。 27.前記HIVパッケージング配列が、5′主要スプライス供与部位からおお よそgag遺伝子の3′末端にあるBal I部位までの十分な数のヌクレオチ ドに対応するセグメント内にある請求項19に記載のベクター。 28.前記プロモーターがウイルスプロモーターである請求項19に記載のベク ター。 29.前記ウイルスプロモーターがSL3プロモーターである請求項28に記載 のベクター。 30.前記予め選択された遺伝子が、trans優性インヒビクー、アンチセン スRNA、触媒RNAまたは可溶伯CD4誘導体をコードする請求項19に記載 のベクター。 31.遺伝子を哺乳動物細胞に移入する方法であって、(a)HIV感染個体の 細胞を請求項19に記載のベクターを用いてトランスフェクトし、 (b)ステップ(a)における細胞が形質転換され、ビリオンを産生するのを待 ち、 (c)ステップ(b)の細胞から産生されたビリオンを他の細胞と接触させて所 望の遺伝子を移入することからなる方法。 32.前記HIV感染個体の細胞をin vivoでトランスフェクトする請求 項31に記載の方法。 33.前記HIV感染個体の細胞をin vitroでトランスフェクトする請 求項31に記載の方法。 34.遺伝子を哺乳動物細胞に移入する方法であって、(a)細胞を請求項19 に記載のベクターを用いてトランスフェクトし、 (b)前記細胞を、全体としては機能性HIVgag、pol、env及び調節 産物を発現するのに十分な数のHIVゲノムに対応するヌクレオチドを含むが、 各ベクターは、全ての機能性HIV gag、pol、env及び調節産物を発 現する十分な数のヌクレオチドは含まない、少なくとも2つのベクターを用いて 同時トランスフェクトし、前記ベクターが、HIV RNAを有効にパッケージ するための5′主要スプライス供与部位とgag遺伝子の間のHIVゲノムのヌ クレオチドに対応する十分な数のヌクレオチドは含まず、前記各ベクターは、そ れらの3′末端に、HIVパッケージング配列によってパッケージされるべきH IV LTRに対応する十分な数のヌクレオチドを含まず、 (c)ステップ(b)で形質転換された細胞を培養してビリオンを産生させ、 (d)ステップ(c)で産生されたビリオンを哺乳動物細胞と接触させる ことからなる方法。 35.前記哺乳動物細胞を組織培養において増殖させる請求項34に記載の方法 。 36.前記哺乳動物細胞が動物宿主細胞中に存在している請求項34に記載の方 法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54074690A | 1990-06-20 | 1990-06-20 | |
US540,746 | 1990-06-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05508320A true JPH05508320A (ja) | 1993-11-25 |
JP3264281B2 JP3264281B2 (ja) | 2002-03-11 |
Family
ID=24156769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51128291A Expired - Lifetime JP3264281B2 (ja) | 1990-06-20 | 1991-06-18 | Hivパッケージング配列を含むベクター、パッケージング不全hivベクター及びその使用 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0536234A4 (ja) |
JP (1) | JP3264281B2 (ja) |
CA (1) | CA2084659A1 (ja) |
WO (1) | WO1991019798A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
DK0630409T3 (da) * | 1992-02-28 | 2003-03-24 | Syngenix Ltd | Defekt-pakkende ikke-onkovirus-vektorer baseret på MPMV |
EP0633942A1 (en) * | 1992-03-27 | 1995-01-18 | Whitehead Institute For Biomedical Research | Non-infectious hiv particles and uses therefor |
EP0644946A4 (en) * | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
WO1994016736A1 (en) * | 1993-01-22 | 1994-08-04 | University Research Corporation | Localization of therapeutic agents |
US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US5837464A (en) * | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
US6200811B1 (en) * | 1996-04-02 | 2001-03-13 | The Regents Of The University Of California | Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein |
US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
WO1999032646A1 (en) | 1997-12-22 | 1999-07-01 | Oxford Biomedica (Uk) Limited | Equine infectious anaemia virus (eiav) based |
CZ137399A3 (cs) * | 1996-10-17 | 1999-07-14 | Oxford Biomedica (Uk) Limited | Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí |
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
WO2001007646A2 (de) * | 1999-07-21 | 2001-02-01 | Martin Heinkelein | Verfahren zur quantifizierung der antiviralen wirkung antiviraler wirkstoffe |
GB0108065D0 (en) * | 2001-03-30 | 2001-05-23 | Syngenix Ltd | Viral vectors |
WO2005118809A2 (en) * | 2004-04-29 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Methods and compositions for enhancing cell adhesion properties |
-
1991
- 1991-06-18 CA CA002084659A patent/CA2084659A1/en not_active Abandoned
- 1991-06-18 EP EP19910912130 patent/EP0536234A4/en not_active Withdrawn
- 1991-06-18 JP JP51128291A patent/JP3264281B2/ja not_active Expired - Lifetime
- 1991-06-18 WO PCT/US1991/004335 patent/WO1991019798A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP3264281B2 (ja) | 2002-03-11 |
EP0536234A1 (en) | 1993-04-14 |
WO1991019798A1 (en) | 1991-12-26 |
EP0536234A4 (en) | 1993-09-15 |
CA2084659A1 (en) | 1991-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5665577A (en) | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof | |
US5981276A (en) | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof | |
EP0386882B1 (en) | Packaging defective HIV provirus, cell lines, and uses thereof | |
Balliet et al. | Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate | |
Parolin et al. | Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes | |
Srinivasakumar et al. | The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines | |
Lisziewicz et al. | Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. | |
JP4190579B2 (ja) | 非分裂細胞への核酸運搬のためのベクターおよび使用方法 | |
Delamarre et al. | A novel human T-leukemia virus type 1 cell-to-cell transmission assay permits definition of SU glycoprotein amino acids important for infectivity | |
JPH05508320A (ja) | Hivパッケージング配列を含むベクター、パッケージング不全hivベクター及びその使用 | |
JPH03504079A (ja) | 組換えレトロウィルス | |
JP2001513643A (ja) | レンチウイルスをベースとするベクター及びベクター系 | |
JP3765103B2 (ja) | Mpmv及びhivに基づく欠損パッケージング非オンコウイルスベクター | |
Etemad-Moghadam et al. | Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys | |
Clements et al. | Molecular basis of the pathobiology of lentiviruses | |
JP2004524813A (ja) | 改良された条件付けで複製するベクター類、それらの生成及び使用方法 | |
LaBonte et al. | Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression | |
US7803582B2 (en) | Recombinant vector and use in gene therapy | |
Bibollet-Ruche et al. | Genetic diversity of simian immunodeficiency viruses from West African green monkeys: evidence of multiple genotypes within populations from the same geographical locale | |
Contag et al. | Simian immunodeficiency virus (SIV) from Old World monkeys | |
US20120034693A1 (en) | Recombinant vector and use in gene therapy | |
EP1183383B1 (en) | Siv-based packaging-deficient vectors | |
JPH05509232A (ja) | 複製効率を増強するためのHIVnef遺伝子を含有する発現ベクター | |
Brdar et al. | Human immunodeficiency virus-1 tat-and tat/nef-defective genomes containing HIV-regulated diphtheria toxin A chain gene inhibit HIV replication | |
Ye | HIV-1 and SIV Nef and Env modulate p21-activated kinase function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071228 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081228 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091228 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091228 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111228 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111228 Year of fee payment: 10 |